SYRE

Spyre Therapeutics (SYRE)

About Spyre Therapeutics (SYRE)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Details

Daily high

$35.06

Daily low

$33.82

Price at open

52 Week High

$35.31

52 Week Low

$10.91

Market cap

2.6B

Dividend yield

0.00%

Volume

1,235

Avg. volume

628,314

P/E ratio

-15.65

Spyre Therapeutics News